This HRD Track test is recommended for:
- Patients with ovarian, breast, pancreatic, or prostate cancer, as these cancers are often linked to HRD.
- Patients undergoing cancer treatment planning, especially for PARP inhibitor therapy.
HRD Track Test (Homologous Recombination Deficiency Status in Tumor)
What is HRD Track Test?
The HRD Track Test is a specialised genetic assay designed to detect Homologous Recombination Deficiency (HRD) in tumor samples. HRD occurs when cells lose the ability to repair DNA damage effectively, leading to genomic instability. This test utilises Next-Generation Sequencing (NGS) to analyse key biomarkers in tumor tissues, including BRCA1, BRCA2, and other HRD-related genes, alongside a Genomic Abberation Score (GAS). Identifying HRD status helps oncologists tailor targeted therapies, particularly PARP inhibitors, for patients with ovarian, breast, prostate, and pancreatic cancers.
Key Features of HRD Track Test
| Category | Description | |
|---|---|---|
| Comprehensive Content | ||
| Advancements in Technology |
Clinical Application of HRD Track Test
- Recommended for patients with advanced (FIGO stage III–IV) epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.
- Ideally be performed at diagnosis of advanced disease, or after completion of first-line platinum-based chemotherapy, especially if the patient achieves a complete or partial response.
- HRD-positive tumors are more likely to respond to PARP inhibitors.
- In patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who achieve a complete or partial response to first-line platinum-based chemotherapy, maintenance therapy with PARP inhibitors significantly improves progression-free survival, particularly in HRD-positive tumors.
Specifications
- Indications: Advanced epithelial ovarian, fallopian tube or primary peritoneal cancer.
- Methodology: Next-Generation Sequencing (NGS).
- Sample Type: FFPE tissue block -Minimum of 20% tumor content; sample should be accompanied by an HPE report and an IHC report
- Accuracy: Sensitivity - 96.3%, Specificity - 98.3%, Accuracy - 97.05%
- Coverage: Identifies variants from complete coding regions & splice boundaries of BRCA1 & 2 genes & 13 HRR genes
HRD Track Test Details
HRD Track Test
Detects: Variants from complete coding regions & splice boundaries of BRCA1 & 2 genes & 13 HRR genes
TAT: 21 working days
Test Code: MGM1892
Key Highlights of MedGenome's HRD Track Test
Comprehensive HRD Assessment
Detects Homologous Recombination Deficiency (HRD) by analysing genomic instability and mutations in HRD-associated genes.
High Sensitivity and Specificity
Validated with a sensitivity of 96.3%, specificity of 98.3%, and accuracy of 97.05% for reliable detection.
Validated for Diverse Clinical Samples
Tested across FFPE tumor specimens, ovarian cancer samples, and known clinical cases of breast, prostate, and pancreatic cancers for robust performance.
Get Genetic Counselling by Our Experts
Connect with Our Experts
MedGenome Patient Stories
MedGenome in the News
Please share your details to get
in touch with our experts.
